Having trouble accessing articles? Reset your cache.

Tenofovir 1% vaginal gel: Interim Phase IIb data

NIH's National Institute of Allergy and Infectious Diseases (NIAID) discontinued the tenofovir 1% vaginal gel arm in the open-label, African Phase IIb VOICE (MTN-003) trial after an interim analysis conducted

Read the full 303 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE